Age-associated loss of skeletal muscle mass and strength, termed sarcopenia, is a major public health concern. Individuals with sarcopenia and frailty have decreased physical function and are at increased risk of cardiovascular and metabolic disorders. Despite the remarkable gains in the human health span, cardiometabolic disorders remain the leading cause of mortality worldwide. Here, we discuss the potential therapeutic implications of promyogenic function promoting anabolic agents, particularly myostatin antagonists, in the prevention of a variety of age-related metabolic disorders.
Keywords: Myostatin, muscle hypertrophy, lipid metabolism, insulin resistance, atherogenesis, Cardiometabolic Disorders, sarcopenia, promyogenic, obesity, diabetes, hepatic steatosis, atherosclerotic heart disease, IGF-1, modulators, Ldlr, ACVRIIB, hypoadiposity, RER, sensitivity, glucose, glucagon, Akt, skeletal muscle, phosphoryation, TNF, leptin, cytokines, myokines, lipolytic, IL-6, Fgf-21, Fstl-1, RNAi, aging, SREBP-1, mRNA, VLDL, LDL, Smad2/3
Rights & PermissionsPrintExport